RxDoctor Payments Data

Nancy Crum Cianflone, MD

Infectious Disease · Bucyrus, OHNPI 1437120557

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (43.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by AbbVie at 56.2% of the total. Reporting peaked in 2019 at $4,227 and has fallen 81.4% since, to $785 in 2025. Among infectious disease clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,598in general payments, 2019–2025

Across 153 payments — averaging $95.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Theratechnologies Inc.$3K
  • Sanofi Pasteur Inc.$2K
  • Merck$365
  • Gilead$317
  • Viiv Healthcare Company$273
  • plus $751 from 13 others

What the payments were for

  • Consulting fees$5,56038%
  • Speaking & faculty fees$6,33043%
  • Travel & lodging$1981%
  • Food & beverage$2,37216%
  • Education$1381%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,598 in reported general payments places this provider in the 90th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio

Medicare billing

Part B allowed, 2024
$146,843
Medicare patients
280
Services billed
1,851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArikayceAmikacin Liposomal/Neb.Accessr14$215,495
Daptomycin20$51,000
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$42,721
Vancomycin Hcl28$8,820
ErtapenemErtapenem Sodium18$8,661
Fosfomycin Tromethamine42$6,155
Cefepime Hcl24$5,713
CeftriaxoneCeftriaxone Sodium34$5,448
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam21$4,352
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst127$4,342
Fluconazole119$2,403
Linezolid45$2,267
CefuroximeCefuroxime Axetil90$2,030
Doxycycline Hyclate131$1,697
Rifampin22$1,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Insmed, Inc.Arikayce$238$215,49514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Bucyrus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →